Last reviewed · How we verify
NCT05205837
A Randomized, Double-blinded, Clinical, Placebo-controlled Trial on the Effects of Therapy With Letrozole and hUman Choriongonadotropin in Male Hypogonadism Induced by Illicit Use of Anabolic Androgenic Steroids- The LUCAS Trial
Phase 4 trial testing Letrozole 2.5mg, hCG in Hypogonadism in 8 participants. Terminated before completion.
15 August 2023
Quick facts
| Lead sponsor | Rigshospitalet, Denmark |
|---|---|
| Phase | Phase 4 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 8 |
| Start date | 24 November 2021 |
| Primary completion | 15 August 2023 |
| Estimated completion | 15 August 2023 |
| Sites | 1 location across Denmark |
Drugs / interventions tested
- Letrozole 2.5mg, hCG — full drug profile →
- Placebo
Conditions studied
- Hypogonadism — all drugs for Hypogonadism →
- Hypogonadism, Male — all drugs for Hypogonadism, Male →
- Hypogonadotropic Hypogonadism — all drugs for Hypogonadotropic Hypogonadism →
Sponsor
Rigshospitalet, Denmark
Who can join
Adults 18 to 50, male only, with Hypogonadism or Hypogonadism, Male. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The overall objective of this randomized trial is to investigate the effects of treatment of AAS- induced male hypogonadism with combined therapy of letrozole and hCG compared with placebo on reproductive hormone levels, adherence to cessation of AAS use, fertility, cardiac function and quality of life.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05205837
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hypogonadism
Currently open trials in the same condition.
- NCT06455969 — Adaptions and Resiliency to Multi-Stressor OpeRations · Phase 4 · recruiting
- NCT06280807 — Observation of Environment and Reproductive-Endocrine Effects · recruiting
- NCT04460872 — Locomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord Injury · Phase 2 · recruiting
- NCT04731376 — Perioperative Testosterone Replacement Therapy for the Improvement of Post-Operative Outcomes in Patients With Low Testo · Phase 1 · active not recruiting
- NCT03887936 — Testosterone Therapy and Bone Quality in Men With Diabetes and Hypogonadism · Phase 4 · active not recruiting
Other Rigshospitalet, Denmark trials
Trials by the same sponsor.
- NCT07401368 — Clinicians' Trust in AI-Based Fetal Growth Estimates · NA · not yet recruiting
- NCT07442357 — The Per-procedural Antibiotic Prophylaxis in Patients Undergoing Transcatheter Aortic Valve Implantation Trial · NA · not yet recruiting
- NCT07528729 — Alcohol as a Modifiable Risk Factor for Atrial Fibrillation · NA · not yet recruiting
- NCT07511439 — Reversible Effects of Oral Contraceptive Removal on Serotonergic Neurotransmission · Phase 4 · not yet recruiting
- NCT07467187 — Invasive Home Ventilation in Denmark · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05205837 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Rigshospitalet, Denmark
- Last refreshed: 15 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05205837.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing